Clinical trial NCT05652101: Hyperekplexia : Adaptative Skills and Neurodevelopmental Trajectory
Official title: Study of Adaptative Skills and Neurodevelopmental Trajectory for Patients With Hyperekplexia (Startle Disease)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hyperekplexia
Keywords: Hyperekplexia
Neurodevelopment trajectory
Adaptative skills
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-12-15
Enrollment: 40
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population of patients followed in pediatric neurology or neurology, for hereditary hyperekplexia

Brief summary: Hereditary hyperekplexia is a rare neuronal disorder, caused by genetic defects leading to dysfunction of glycinergic neurotransmission.

The clinical presentation is characterized by stiffness and exaggerated startle responses to unexpected stimuli, that appear shortly after birth.

The generalised stiffness can lead to apnea and sudden infant death syndrome.

Several genes are known to be associated with hereditary hyperekplexia. The most frequent are Glycine Receptor Alpha 1 (GLRA1), Glycine Receptor Beta (GLRB) and Solute Carrier Family 6 Member 5 (SLC6A5). They encode for the postsynaptic glycine receptor (GLRA1, GLRB) and the presynaptic glycine transport (SLC6A5). Genetic mutations in these genes lead to dysfunction in the glycinergic inhibitory neurotransmission.

The neurodevelopment was initially described as normal, or as delayed due to the motor difficulties. Global development delay and intellectual disability are reported as well, in the most recent studies.

Nevertheless, the degree of severity of the learning difficulties and the adaptive faculties of the patients is not specified.

Similarly, the efficacy of clonazepam in hyperekplexia is well known, but the evolution of dosage over time and the frequency of complete withdrawal have never been studied.

The primary endpoint of this study is to describe adaptive skills using a standardized questionnaire, Vineland Adaptive Behavior Scale (VABS2).

Secondary endpoints are:

* Neurodevelopmental course study
* Description of the evolution of the clinical manifestations over the years
* Evaluation of the efficacity of the treatment CLONAZEPAM, initially and over time, and evolution of the dosage
* Comparison of clinical and therapeutical characteristics according to the genotype


Eligibility criteria: Inclusion Criteria:

* Clinical diagnostic criteria for hyperekplexia (see Thomas et al. BRAIN, 2013):

  * The presence of hypertonia (either hypertonia on examination, axial or segmental, or access of stiffness)
  * Exaggerated reflex startles, to auditory, tactile or visual stimuli
  * The presence of reflex bursts on percussion of the midline
* Children \>2 years and adults
* No opposition of one of the two parents (or legal representative) or of the adult patient

Exclusion Criteria:

* The presence of a cause secondary to the hyperekplexia (traumatic, autoimmune, etc.)
* The presence of another cause for a delay in psychomotor development (other neurological pathology, serious head trauma, etc.)
* Pregnant or breastfeeding women
* Person deprived of liberty by judicial or administrative decision

Primary outcomes:
measure: VABS2 total score and specific scores (socialization, communication, daily living and motricity)
timeFrame: maximum 2 months after the inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hopital Femme Mère Enfant
Study officials:
References: